Laura Weisbach

Ms. Laura Weisbach

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 March 2022 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
LWLaura Weisbach
Laura Weisbach
ASAnna K. Schuster
Anna K. Schuster
MHMichael Hartmann
Michael Hartmann
MFMartin F. Fromm
Martin F. Fromm
RMRenke Maas
Renke Maas
KFKatrin Farker
Katrin Farker
Liver disease is a common condition worldwide that can cause alterations in drug disposition and susceptibility to drug toxicities, with increased risk of adverse drug reactions. European Summaries of Product Characteristics (SmPCs) and United States Prescribing Information (US PI) should therefore be comprehensible to prescribers regarding their liver-associated contraindications to ensure safe prescribing. This study aimed to evaluate the ambiguity of terminology used in communicating liver-associated absolute contraindications in SmPCs/PI of commonly prescribed drugs in four major drug markets (Germany, Switzerland, the United Kingdom, and the United States) by assigning wordings to different categories and analyzing their clinical comprehensibility. For US PI, 79% did not contain liver-related contraindications, compared to 2, 13, and 6% of German, Swiss, and British SmPCs, respectively. Study findings indicate that out of 228 examined SmPCs/PI containing liver-related contraindications, 77, 79, 76, and 52% contained unclear wording in the German, Swiss, British, and American drug market, respectively. Only 40% (German), 52% (Swiss), 39% (British), and 29% (American) of SmPCs/PI included terms with explicit wording. Including more precise statements in SmPCs/PI based on laboratory parameters (such as albumin) or scores (e.g., the Child–Pugh score) to objectify the severity of liver disease may improve the clarity of SmPCs/PI and the safety of drug prescription.

17 April 2023 in British Journal of Clinical Pharmacology
Verified
Journal Article
Open access
LWLaura Weisbach
Laura Weisbach
ASAnna K. Schuster
Anna K. Schuster
MHMichael Hartmann
Michael Hartmann
PDPauline Dürr
Pauline Dürr
MTMelanie I. Then
Melanie I. Then
KFKatrin Farker
Katrin Farker
Aims: Prescribing information should follow a defined structure to help prescribers easily find required information. Often information appears in different sections of Summaries of Product Characteristics (SmPCs) in an inconsistent way. Still unknown is how this inconsistency affects absolute contraindications and how it can be improved. Thisstudy aimed to evaluate the structure of absolute contraindications in SmPCs based on absolute drug–drug contraindications (DDCI) in the section ‘contraindications’ and references to sections ‘special warnings and precautions for use’ (here as ‘warnings’) and ‘interaction with other medicinal products and other forms of interaction’ (here as ‘interactions’).Methods: SmPCs of 693 commonly prescribed drugs were analysed regarding absolute DDCI in ‘contraindications’ sections. References to sections on ‘warnings’ and ‘interactions’ were evaluated to characterize information provided about DDCI.Results: Of 693 analysed SmPCs, 138 (19.9%) contained ≥1 absolute DDCI. Of 178 SmPCs that referred to sections on ‘warnings’ or ‘interactions’, 131 (73.6%) did not contain further information on absolute DDCI, whereas 47 (26.4%) did. Such additional information was found in sections on ‘interactions’ and ‘warnings’ in 41 (87.2%) and 9 (19.1%) SmPCs, respectively.Conclusions: Information regarding absolute DDCI was found not only in sections on ‘contraindications’ but also in sections on ‘warnings’ and ‘interactions’. Information was not given with consistently straightforward phrasing and structure and so can leave uncertainty for prescribers. To improve drug safety, clear definitions and wording for absolute and relative contraindications should be provided, ideally in tables.

7 November 2024 in British Journal of Clinical Pharmacology
Verified
Journal Article
Open access
WAWahram Andrikyan
Wahram Andrikyan
MSMichael I. Sponfeldner
Michael I. Sponfeldner
LJLea Jung-Poppe
Lea Jung-Poppe
PDPauline Dürr
Pauline Dürr
MSMelanie I. Straubmeier
Melanie I. Straubmeier
RMRenke Maas
Renke Maas
Aims: Previous work has identified several limitations in “Summaries of Product Characteristics” (SmPCs), which are associated with risks for patients. The aim of this study was to evaluate pharmacists' and physicians' interpretation of contraindications in SmPCs and reasons for their nonadherence in clinical routine.Methods: For 20 commonly missed or ignored absolute contraindications, an anonymous online survey providing 24 clinical example cases (one or two per contraindication) for physicians and pharmacists was developed. Experts in medication safety were asked whether the respective case fulfilled the definition of the contraindication in the SmPC: (a) formally, irrespective of the clinical relevance of the contraindication (17 cases), and (b) whether the contraindication was deemed clinically relevant in each respective case (24 cases).Results: Twenty‐seven pharmacists and 27 physicians completed the survey. For only one case (1/17; 5.8%) did all experts agree on the same answer option regarding the formal fulfilment of a given contraindication statement. Experts gave heterogeneous answers regarding the interpretation of a contraindication. For instance, among 10 predefined answer options for the contraindication “active liver disease” in the SmPC of simvastatin, every option was selected by at least six experts. In 17/24 (70.8%) clinical example cases a majority of experts agreed on the clinical relevance of a given contraindication. Key reasons for nonadherence to contraindications were “patient monitoring possible”, “lack of alternative treatment” and “acute/severe situations”.Conclusions: Experts' disagreement on the interpretation of contraindications in SmPCs using clinical example cases indicates that further efforts are needed to improve their usability in clinical routine.

25 November 2024 in Journal of Public Health
Verified
Journal Article
Open access
PDF file
ASAnna Kathrin Schuster
Anna Kathrin Schuster
MKMiriam Kesselmeier
Miriam Kesselmeier
LWLaura Weisbach
Laura Weisbach
CSChristoph Stumme
Christoph Stumme
WBWilhelm Behringer
Wilhelm Behringer
KFKatrin Farker
Katrin Farker
Aim: Falls are common adverse events, often leading to hospitalization with adverse effects on the physiological and psychological health of patients. Although risk factors for falls are well examined, it is difficult to identify fallers through their electronical health records (EHR). This study investigates whether EHR contain characteristics that indicate a fall before hospitalization. Subject and methods: We evaluated 500 EHR of patients hospitalized through the Department of Emergency Medicine of Jena University Hospital. We considered electronically available characteristics including free texts and ICD-10-GM codes. Inpatients with and without a fall event previous to their hospitalization were compared for significant differences in EHR characteristics. Therefore, we applied the Mann–Whitney U test and the exact Fisher test, respectively, with a two-sided significance level of 0.05 and without correction for multiple testing. Results: It was possible to identify significant differences between fallers and non-fallers by gender (66.3% women), age (median: 84 years), living situation prior to hospital admission (20.5% from nursing home, 41.1% living alone) and type of discharge. Besides other risk factors, ICD-10-GM codes included injuries, especially fractures and superficial injuries, but also cognitive deficits, incontinence, and physical limitations were more prevalent with fallers than non-fallers. Conclusion: This study identified characteristics that can support identification of fall patients through EHR. Such information should be tested in other hospitals and is expected to enhance patient safety and utilization of healthcare resources.